Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction

American Journal of Health-System Pharmacy

Volumn 56, Issue 17, 1999, Pages 1726-1732

  Elliott, William J ^a,c   Weir, David R ^b  

^a RUSH MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Age; Antilipemic agents; Atorvastatin; Cerivastatin; Coronary disease; Economics; Fluvastatin; Lovastatin; Mortality; Myocardial infarction; Pravastatin; Simvastatin

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; HEART DEATH; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RECURRENT DISEASE; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 0033198903     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.17.1726     Document Type: Article

References (40)

1. 1998 heart and stroke statistical update. Dallas: American Heart Association; 1998.
2. Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Arch Intern Med. 1992; 152:56-64.
3. LaRosa JC, Hunningshake D, Bush D et al. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease: a joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Circulation. 1990; 81:1721-33.
4. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 1995; 76:69C-77C.
5. Summary of the second report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP II). JAMA. 1993; 269:3015-23.
6. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-9.
7. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339:1349-57.
8. Sacks FM, Pfeffer MA, Moye LA et al., for the CARET Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-9.
9. Lipid Research Clinics Program. Lipid Research Clinics Coronary Primary Prevention Trial results. JAMA. 1984; 251:351-4.
10. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333:1301-7.
11. Downs JR, Clearfield M, Weis S et al., for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998; 279: 1615-22.
12. Avorn J, Monette J, Lacour A et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998; 279:1458-62.
13. Andrade SE, Walker AM, Gottlieb LK et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995; 332:1125-31.
14. Choice of lipid-lowering drugs. Med Lett Drugs Ther. 1998; 40: 117-22.
15. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995; 345:1274-5.
16. Grover SA, Coupai L, Paquet S et al. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventive coronary and cerebrovascular events. Arch Intern Med. 1999; 159:593-600.
17. Johannesson M, Jønsson G, Kjekshus J et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 1997; 336:332-6.
18. Schulman KA, Kinosian B, Jacobson TA et al. Reducing high blood cholesterol level with drugs: cost-effectiveness of pharmacologic management. JAMA. 1990; 264:3025-33.
19. Goldman L, Weinstein MC, Goldman PA et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 1991; 265:1145-51.
20. Ashraf T, Hay JW, Pitt B et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1998; 78:409-14.
21. National Center for Health Statistics. Vital statistics of the USA, 1992, volume II: mortality, part A. Hyattsville, MD: U.S. Department of Health and Human Services; 1995.
22. Hennekens CH, Albert CM, Godfried SL et al. Adjunctive drug therapy of acute myocardial infarction - evidence from clinical trials. N Engl J Med. 1996; 335:1660-7.
23. Garg R, Yusuf S, for the Collaborative Group on ACE-Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995; 273:1450-6.
24. Weinstein MC, Seigel JE, Gold MR et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996; 276:1253-8.
25. Aguirre FV. The cost of an open infarct-related artery: comparison of treatment modalities in the reperfusion era. Mayo Clin Proc. 1994; 69:87-9.
26. Garrett HM, ed. Red book update. Montvale, NJ: Medical Economics Data; 1999 Feb.
27. Munroe WB, Kunz K, Dalmade-Israel C et al. Economic evaluation of pharmacist involvement in disease management in a community pharmacy setting. Clin Ther. 1997; 19:113-23.
28. Kelly ET III, Rodowskas CA Jr, Gagnon JP. An examination of the effect of market demographic and competitive characteristics on gross margins of prescription drugs. Med Care. 1975; 13:956-65.
29. Kellick KA, Burns K, McAndrew E et al. Focus on atorvastatin: an HMG-CoA reductase inhibitor for lowering both elevated LDL-cholesterol and trigylcerides in hypercholesterolemic patients. Formulary. 1997; 32:352-63.
30. McClellan KJ, Wiseman LR, McTavish D. Cerivastatin. Drugs. 1998; 55:415-20.
31. Corsinl A. Cerivastatin: a viewpoint. Drugs. 1998; 55:421.
32. Elliott WJ, Weir DR, Hoelscher DD et al. Cost-effectiveness of pharmacological interventions after myocardial infarction. Circulation. 1994; 90:I-528. Abstract.
33. Johannesson M. The impact of age on the cost-effectiveness of hypertension treatments: an analysis of randomized drug trials. Med Decis Making. 1994; 14:236-44.
34. Kupersmith J, Holmes RM, Hogan A et al. Cost-effectiveness analysis in heart disease, part I: general principles. Prog Cardiovasc Dis. 1994; 37:161-84.
35. Jønsson BG. Cost-benefit of treating hypertension. J Hypertens Suppl. 1994; 12:565-75.
36. Physicians' desk reference. 51st ed. Montvale, NJ: Medical Economics; 1999.
37. Sacks FM, Moye LA, Davis BR et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. Circulation. 1998; 97:1446-52.
38. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998; 97:1440-5.
39. Pedersen TR, Olsson AG, Faergeman O et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study. Circulation. 1998; 97:1453-60.
40. Cerivastatin for hypercholesterolemia. Med Lett Drugs Ther. 1998; 40:13-4.